435 related articles for article (PubMed ID: 28842283)
1. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection.
Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M;
Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283
[TBL] [Abstract][Full Text] [Related]
2. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
[TBL] [Abstract][Full Text] [Related]
3. Risk factors and mortality for patients with Bloodstream infections of Klebsiella pneumoniae during 2014-2018: Clinical impact of carbapenem resistance in a large tertiary hospital of China.
Chang H; Wei J; Zhou W; Yan X; Cao X; Zuo L; Chen S; Yao K; Huang R; Chen Y; Wu C
J Infect Public Health; 2020 May; 13(5):784-790. PubMed ID: 31843651
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology, management, and outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections in hospitals within the same endemic metropolitan area.
Cristina ML; Alicino C; Sartini M; Faccio V; Spagnolo AM; Bono VD; Cassola G; De Mite AM; Crisalli MP; Ottria G; Schinca E; Pinto GL; Bottaro LC; Viscoli C; Orsi A; Giacobbe DR; Icardi G;
J Infect Public Health; 2018; 11(2):171-177. PubMed ID: 28668656
[TBL] [Abstract][Full Text] [Related]
5. The effect of colistin resistance and other predictors on fatality among patients with bloodstream infections due to Klebsiella pneumoniae in an OXA-48 dominant region.
Menekşe Ş; Çağ Y; Işık ME; Şahin S; Hacıseyitoğlu D; Can F; Ergonul O
Int J Infect Dis; 2019 Sep; 86():208-211. PubMed ID: 31402295
[TBL] [Abstract][Full Text] [Related]
6. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey.
Trecarichi EM; Pagano L; Martino B; Candoni A; Di Blasi R; Nadali G; Fianchi L; Delia M; Sica S; Perriello V; Busca A; Aversa F; Fanci R; Melillo L; Lessi F; Del Principe MI; Cattaneo C; Tumbarello M;
Am J Hematol; 2016 Nov; 91(11):1076-1081. PubMed ID: 27428072
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC
Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for recurrent carbapenem resistant Klebsiella pneumoniae bloodstream infection: a prospective cohort study.
Giannella M; Graziano E; Marconi L; Girometti N; Bartoletti M; Tedeschi S; Tumietto F; Cristini F; Ambretti S; Berlingeri A; Lewis RE; Viale P
Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1965-1970. PubMed ID: 28567543
[TBL] [Abstract][Full Text] [Related]
9. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
[TBL] [Abstract][Full Text] [Related]
10. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study.
Geng TT; Xu X; Huang M
Medicine (Baltimore); 2018 Feb; 97(8):e9961. PubMed ID: 29465589
[TBL] [Abstract][Full Text] [Related]
11. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy.
Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC
Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study.
Giannella M; Trecarichi EM; De Rosa FG; Del Bono V; Bassetti M; Lewis RE; Losito AR; Corcione S; Saffioti C; Bartoletti M; Maiuro G; Cardellino CS; Tedeschi S; Cauda R; Viscoli C; Viale P; Tumbarello M
Clin Microbiol Infect; 2014 Dec; 20(12):1357-62. PubMed ID: 24980276
[TBL] [Abstract][Full Text] [Related]
13. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
Neuner EA; Yeh JY; Hall GS; Sekeres J; Endimiani A; Bonomo RA; Shrestha NK; Fraser TG; van Duin D
Diagn Microbiol Infect Dis; 2011 Apr; 69(4):357-62. PubMed ID: 21396529
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of dual colistin- and carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A single-center retrospective study of 75 cases in India.
Kaur A; Gandra S; Gupta P; Mehta Y; Laxminarayan R; Sengupta S
Am J Infect Control; 2017 Nov; 45(11):1289-1291. PubMed ID: 28807425
[TBL] [Abstract][Full Text] [Related]
15. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae.
Falcone M; Bassetti M; Tiseo G; Giordano C; Nencini E; Russo A; Graziano E; Tagliaferri E; Leonildi A; Barnini S; Farcomeni A; Menichetti F
Crit Care; 2020 Jan; 24(1):29. PubMed ID: 32000834
[TBL] [Abstract][Full Text] [Related]
16. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections.
Viale P; Giannella M; Lewis R; Trecarichi EM; Petrosillo N; Tumbarello M
Expert Rev Anti Infect Ther; 2013 Oct; 11(10):1053-63. PubMed ID: 24073806
[TBL] [Abstract][Full Text] [Related]
17. Impact of carbapenem-resistant Klebsiella pneumoniae (CR-KP) infections in kidney transplantation.
Varotti G; Dodi F; Terulla A; Santori G; Mariottini G; Bertocchi M; Marchese A; Fontana I
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28796391
[TBL] [Abstract][Full Text] [Related]
18. Risk factors, outcomes and genotypes of carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infection: a three-year retrospective study in a large tertiary hospital in Northern China.
Zheng SH; Cao SJ; Xu H; Feng D; Wan LP; Wang GJ; Xiao XG
Infect Dis (Lond); 2018 Jun; 50(6):443-451. PubMed ID: 29303020
[TBL] [Abstract][Full Text] [Related]
19. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality.
Capone A; Giannella M; Fortini D; Giordano A; Meledandri M; Ballardini M; Venditti M; Bordi E; Capozzi D; Balice MP; Tarasi A; Parisi G; Lappa A; Carattoli A; Petrosillo N
Clin Microbiol Infect; 2013 Jan; 19(1):E23-E30. PubMed ID: 23137235
[TBL] [Abstract][Full Text] [Related]
20. Mortality in KPC-producing Klebsiella pneumoniae bloodstream infections: a changing landscape.
Giacobbe DR; Marelli C; Cattardico G; Fanelli C; Signori A; Di Meco G; Di Pilato V; Mikulska M; Mazzitelli M; Cattelan AM; Pallotto C; Francisci D; Calabresi A; Lombardi A; Gori A; Del Bono V; Aldieri C; Losito AR; Raffaelli F; Cortegiani A; Milazzo M; Del Puente F; Pontali E; De Rosa FG; Corcione S; Mularoni A; Russelli G; Giacomini M; Badalucco Ciotta F; Oltolini C; Serino FS; Momesso E; Spinicci M; Graziani L; Torti C; Trecarichi EM; Merli M; D'Amico F; Marchese A; Vena A; Bassetti M
J Antimicrob Chemother; 2023 Oct; 78(10):2505-2514. PubMed ID: 37606528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
